Led · Equity · Apr 2026

MAECONOMY develops a platform that digitises building- and material-level data to track, trace and transact materials within the built environment. Its technology combines AI-driven material mapping, digital material passports, and blockchain-based trading infrastructure to standardise, verify and enable pre-extraction trading of materials. The company positions buildings and infrastructure as liquid, asset-backed reserves to unlock previously invisible economic and environmental value. MAECONOMY says this approach enables circular reuse at scale, supports measurable CO₂ reductions, and helps compliance with emerging EU frameworks such as the CSRD and the EU Taxonomy. The firm notes that over one-third of all waste in the EU comes from construction and demolition and aims to capture residual material value that current systems miss. MAECONOMY was founded in 2023, is operating in the Netherlands, and is working with municipalities and institutional asset owners while exploring broader expansion.

Participated · Equity · Dec 2025

Mosa Meat develops cultivated (lab-grown) meat products and has demonstrated its underlying technology, according to Invest International. The company is pursuing international market entry and intends to target Singapore, the United Kingdom, Australia, Canada and the United States. Current plans include validating those markets, setting up production and supply-chain partnerships, and progressing regulatory approval trajectories. Mosa Meat does not yet have authorization to sell its cultivated products. Its recent €875,000 financing from Invest International is a repayable development contribution aimed at enabling market validation and commercial rollout. The company must still overcome regulatory hurdles, scale production and solve market-introduction challenges before its products can reach supermarket shelves.

Participated · Series A · Nov 2025

Qorium is a Dutch biotechnology company that engineers real leather by cultivating a small sample of animal cells, eliminating the need for livestock farming. The process yields uniform, high-performance leather while sharply reducing waste and environmental impact compared with conventional hides. Based in Maastricht, the firm is now installing larger bioreactor systems in its facilities and has already secured several commercial partnerships to bring its material to market. Management claims the product outperforms traditional leather on consistency and sustainability metrics. Prior to its latest raise, the company had attracted €8 million in seed funding to prove out its science. The new capital will allow Qorium to scale production, expand its team, and move closer to full commercialisation. Investors cite the technology’s potential to transform one of the world’s most polluting industries as a key driver of their support.

Participated · Equity · May 2025

Hy2Care develops CartRevive, a proprietary hydrogel implant designed to repair damaged cartilage in a minimally invasive way. The company recently received FDA Investigational Device Exemption (IDE) approval to begin clinical evaluation of CartRevive in the U.S. Hy2Care has raised new capital to prepare for a U.S. clinical trial and to support early commercialisation steps in Europe and other global markets. The €4.5M financing comes as the firm positions itself within a growing regenerative orthopaedics market; the U.S. cartilage repair market is projected to exceed $1.6 billion by 2030. Investors include the European Innovation Council (EIC) Fund, existing shareholders led by Brightlands Venture Partners, and new participation from regional development agency LIOF.

Participated · Seed · Dec 2023

Ansana focuses on improving hospital sterilisation processes through its flagship product, SteriWatch. The system monitors and manages sterilisation workflows, aiming to reduce human error, boost efficiency, and ultimately enhance patient safety. By delivering real-time insights, SteriWatch helps hospital staff track instruments and ensure compliance with hygiene standards. Ansana intends to use its newly secured capital to advance product development and expand commercial deployments. Although detailed operating metrics such as revenue or user count were not disclosed, the company positions itself to address a critical need in healthcare operations. Future plans likely include broader market rollout across European healthcare facilities and continued R&D to refine the platform’s feature set.